作为卫浴行业的头部家居企业，帝欧家居迎来了新控股股东。 6月5日晚间，帝欧家居（002798.SZ）发布公告称，公司实控人刘进、陈伟、吴志雄与朱江于6月5日签 署了《一致行动协议》，公司实控人变更为朱江、刘进、陈伟、吴志雄。 刘进、陈伟、吴志雄、朱江以及朱江的一致行动人合计持有帝欧家居权益比例为26.46%。与此同时， 四位实控人在上市公司可转债转股、一致行动、推动上市公司可转债的有效化解、流动性支持等方面达 成战略合作。 据每日经济新闻，1983年出生的朱江，在金融机构历练多年后，开始进军资本市场。他曾涉足三泰控股 （川发龙蟒前身）、三五互联（琏升科技前身）和迅游科技。 在公司控制权可能发生变更的背后，是帝欧家居近年来业绩和资产状况上的承压。 帝欧家居是国内最早一批卫浴生产制造企业，后通过并购方式延伸至陶瓷产业，公司在成都、重庆、佛 山、广西、景德镇地区拥有六个建筑陶瓷、卫生洁具生产基地。 在朱江正式"入主"之前，上市公司股价"抢跑"。帝欧家居停牌前两日，6月2日、3日，公司股价、债券 价格双双先行大涨，累计涨幅分别为14.72%、8.51%。从三月朱江等开始增持帝欧家居以来，公司股价 累计涨幅已经超过47 ...

Core Viewpoint - The control of Diou Home (SZ002798) has changed hands to Zhu Jiang, Liu Jin, Chen Wei, and Wu Zhixiong as of June 5, 2023, following the signing of a concerted action agreement. Zhu Jiang is the actual controller of Chengdu Shuihua Hulian Technology Co., which holds 100% of Chengdu Shuihua Zhiyun Technology Co., a significant shareholder of Diou Home [1][2][4]. Group 1: Control Change and Shareholding - On June 5, 2023, Diou Home announced a change in its actual controller to Zhu Jiang and others, indicating a shift in company governance [1][4]. - As of the announcement date, Zhu Jiang and his concerted actors hold a combined 26.46% equity in Diou Home, establishing them as the actual controllers [4][6]. - Prior to this, on May 17, 2023, Shuihua Zhiyun had increased its stake in Diou Home, acquiring approximately 12.87 million shares and 526,200 convertible bonds, bringing their total equity to 5.000011% [2][4]. Group 2: Financial Performance and Challenges - Diou Home has faced declining performance and asset conditions, with a reported accumulated deficit of 1.258 billion yuan as of December 31, 2024, exceeding one-third of its paid-in capital of 394 million yuan [6]. - The company operates in the bathroom and building ceramics sector, with brands including "Diwang" sanitary ware and "Oushinou" ceramics [5][6]. Group 3: Zhu Jiang's Background - Zhu Jiang, born in 1983, is an experienced player in the capital market, having previously been involved with companies such as San Tai Holdings and San Wu Hulian [1][7]. - He has held significant positions in various financial institutions and has been a key figure in several companies, showcasing his extensive experience in corporate governance and investment [8][9].

Group 1 - The controlling shareholder of the company is planning a change in control, leading to a suspension of the company's stock starting June 6, 2025 [2][4][6] - The stock suspension is expected to last no more than two trading days to ensure fair information disclosure and protect investor interests [6] - The company has recently faced regulatory penalties due to internal control issues, with warnings issued to two former chairmen and related management personnel [8][10] Group 2 - An investigation revealed that the company's subsidiary signed supplementary agreements with certain clients and promoters that were not included in the internal control management system, resulting in inaccurate information disclosure [10] - The company is primarily engaged in the research, development, production, and sales of blood products, which are critical national strategic reserve materials and emergency medications for major diseases [10] - The company aims to enhance its profitability by increasing product quantity through R&D innovation and plans to expand its blood product business while actively exploring a second growth avenue for sustainable development [10] Group 3 - As of June 5, the company's stock price was 16.96 yuan per share, with a total market capitalization of 16.1 billion yuan [11]

Group 1 - The core point of the announcement is the signing of a supplementary agreement regarding the delegation of voting rights, indicating a potential change in control of the company [1][2] - The controlling shareholder, Sun Jianxi, intends to transfer 34,936,110 shares, representing 11% of the total shares, to Shanghai Mangrui Enterprise Management Partnership [1][2] - Following the transfer, the total shares held by Sun Jianxi and Li Taijie will be 57,812,390 shares, which accounts for 18.20% of the total shares [2][4] Group 2 - The supplementary agreement modifies certain terms of the original voting rights delegation agreement, confirming the delegation of voting rights for 57,812,390 shares [3][4] - The previous number of delegated shares was 41,932,340, which represented 13.20% of the total shares, indicating an increase in the delegated voting rights [4] - The implementation of this equity change is subject to compliance review by the Shenzhen Stock Exchange and the China Securities Depository and Clearing Corporation [4]

Core Viewpoint - Filinger's control change is expected to resolve long-standing internal conflicts and improve performance, following the announcement of a share transfer agreement that will change the actual controller from Ding Furu to Jin Yawei, with the German shareholders exiting [2][4][9] Group 1: Control Change Announcement - Filinger announced a control change after a one-day suspension, with Ding Furu and his associates transferring 88,872,943 shares at a price of 7.88 yuan per share, representing 25% of the total share capital [3] - The German shareholder, Filinger Holdings, transferred 96,764,554 shares at a price of 6.73 yuan per share, accounting for 27.22% of the total share capital [4] - Following the transfer, Ding Furu and his associates will retain 19.56% of the voting rights [4] Group 2: Internal Conflicts - The conflict between Chairman Jürgen Vöhringer and Vice Chairman Ding Furu has escalated, with Vöhringer unable to guarantee the authenticity of the annual report for two consecutive years due to issues with related party transactions [5][6] - Filinger has faced scrutiny from the China Securities Regulatory Commission for failing to disclose related party transactions properly, leading to criticism of Ding Furu [6][8] Group 3: Financial Performance - Filinger's revenue for 2024 is reported at 336 million yuan, a year-on-year decline of 14.86%, with a net loss of 37.31 million yuan compared to a loss of 24.18 million yuan in 2023 [8] - In the first quarter of 2024, the company reported revenue of 33.89 million yuan, down 33.94% year-on-year, with a net loss of 13.67 million yuan [8] Group 4: Market Reaction - Filinger's stock price hit the daily limit on May 30, closing at 8.22 yuan per share, prior to the announcement of the control change [4][9] - Following the announcement on June 4, the stock price again reached the daily limit, closing at 9.04 yuan per share [2]

Core Viewpoint - The article discusses the significant share transfer of Feiling Group, where the actual controller will change from Ding Furui to Jin Yawei, leading to a complete exit of the largest shareholder, Feiling Group Holdings [1][2]. Share Transfer Details - Ding Furui and his associates plan to transfer 88,872,943 shares (25% of total shares) to Anji Yiqing at a price of 7.88 yuan per share, totaling approximately 700 million yuan [6][8]. - Feiling Group Holdings will transfer 96,764,554 shares (27.22% of total shares) to various entities at a price of 6.73 yuan per share, totaling about 650 million yuan [7][8]. - After the transactions, Ding Furui's shareholding will decrease to 19.56%, while Jin Yawei and Anji Yiqing will hold 25% of the company, gaining control [7]. Company Background and Performance - Feiling Group, established in 1995, primarily produces solid wood and composite flooring and was listed in 2017 [10]. - The company has faced declining performance, with revenues dropping from 602 million yuan in 2020 to 336 million yuan in 2024, and net profits turning negative in recent years [11]. - Internal conflicts have arisen between foreign shareholders and Ding Furui, leading to frequent management changes and resignations [11]. Related Transactions and Issues - The company has been involved in undisclosed related party transactions, including significant construction contracts with companies controlled by Ding Furui, which were not properly disclosed [12]. - Prior to the major share transfer, Feiling Group Holdings had already initiated a plan to reduce its holdings by up to 10,664,700 shares [13][14]. New Controller's Profile - Jin Yawei, the new actual controller, has multiple investment companies and private equity funds, with plans to leverage his resources for the sustainable development of Feiling Group [16]. - Jin Yawei has been active in the capital market, including plans to acquire shares in other companies, indicating a strategic approach to investment [17].

Core Viewpoint - *ST Jinbi's controlling shareholders are planning a share transfer, leading to a temporary suspension of trading from June 5, 2025, for up to two trading days [2][5]. Group 1: Share Transfer and Control Change - The controlling shareholders, Lin Haoliang and Lin Ruowen, are in preliminary discussions regarding the share transfer, but details such as the identity of the buyer, transfer ratio, and transaction price have not been disclosed [5]. - This control change is part of a broader strategy as *ST Jinbi accelerates its transformation from a focus on maternal and infant consumer products to a dual business model that includes "maternal and infant products + medical beauty services" [5][6]. Group 2: Stock Performance and Market Reaction - *ST Jinbi's stock was suspended from trading on June 5, 2025, after closing at a 5.08% increase on June 4, 2025, with a total market capitalization reaching 2.199 billion yuan [9]. - Since April 29, 2025, the stock has shown a cumulative increase of 42.11%, indicating strong performance within the ST sector [9]. Group 3: Financial Performance - The financial situation of Jinfa Labi shows some pressure, with the 2024 annual report indicating a total profit of 70.7693 million yuan and a net profit of 49.6867 million yuan, but a negative net profit of 45.3168 million yuan after excluding non-recurring gains and losses [10]. - The company has been under delisting risk warning since April 24, 2025, due to its financial performance [10]. - In the first quarter of 2025, the company reported a revenue of 76.0633 million yuan, a year-on-year increase of 74.85%, primarily due to the consolidation of additional subsidiaries [10].

Core Viewpoint - The control of Yiming Pharmaceutical (002826.SZ) is changing hands from its founder Gao Fan to Beijing Fuhai, with the new actual controller being Yao Jinbo, marking a significant shift in the company's ownership structure [2][3][8]. Group 1: Ownership Change - Gao Fan signed a share transfer agreement to sell 23% of his shares to Beijing Fuhai at a price of 15.10 yuan per share, totaling 662 million yuan [2]. - Following the announcement, Yiming Pharmaceutical's stock resumed trading and hit the daily limit up, opening at 13.40 yuan per share [2]. - The new controller, Yao Jinbo, is also the chairman and CEO of 58.com and holds a significant stake in Kuaigou Dache [3][4]. Group 2: Financial Commitments - The share transfer agreement includes performance commitments, with a revenue target of no less than 600 million yuan annually from 2025 to 2027, and a net profit target of at least 30 million yuan for the same period [8]. - If performance targets are not met, Gao Fan will provide compensation based on specific conditions outlined in the agreement [8]. Group 3: Company Performance - Yiming Pharmaceutical's revenue for 2022, 2023, and projected 2024 are 857 million yuan, 667 million yuan, and 652 million yuan respectively, with net profits of 44 million yuan, 15 million yuan, and 46 million yuan [9]. - The company has shown a decline in revenue and profitability, with a significant reliance on its diabetes drug, Miglitol, which generated 474 million yuan in 2024, accounting for 72.72% of total revenue [9]. - The cardiovascular product, Guo Loupian injection, has seen a drastic revenue drop of 55.61% in 2024, leading to the termination of its partnership with Shanghai Pharmaceutical Group [9][10].

蔡南桂先生、唐霖女士拟向海南雅亿转让其持有的公司 14.16%股份。同时，蔡南 桂先生、唐霖女士承诺自本次交易交割日起至其不再持有上市公司股份之日止， 无条件且不可撤销地承诺放弃行使其所持标的公司剩余股份所对应的除收益权 和股票处置权之外的全部股东权利。上述事项可能导致本公司控股股东及实际控 制人发生变更,该事项尚需取得深圳证券交易所合规性确认后方可实施，能否最 终完成及完成时间尚存在不确定性。敬请广大投资者关注相关公告并注意投资风 险。 证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-031 赛隆药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 券简称：*ST 赛隆，证券代码：002898）于 2025 年 5 月 30 日、6 月 3 日、6 月 4 日连续 3 个交易日收盘价格涨幅累计偏离 15.44%，根据深圳证券交易所有关规 定，属于股票交易异常波动的情况。截至 2025 年 6 月 4 日，公司股票交易连续 规定，属于股票交易严重异常波动的情况。 率为-68.98，市净率为 4.59。公司所属 ...

中国经济网北京6月4日讯 菲林格尔(603226.SH)今日复牌，股价涨停。截至发稿，菲林格尔报9.04元， 上涨9.98%。 此前，菲林格尔于2025年5月30日收到公司实际控制人丁福如的通知，实际控制人丁福如正在筹划公司 股份协议转让事宜，该事项可能导致公司控制权发生变更。鉴于上述事项正在洽谈当中，尚存在不确定 性，为保证公平信息披露，维护投资者利益，避免造成公司股价异常波动，公司股票（证券代码： 603226，证券简称：菲林格尔）于2025年6月3日（星期二）开市起停牌。 停牌前一个交易日（5月30日），菲林格尔股价涨停，收报8.22元，上涨10.04%。 菲林格尔昨晚披露的关于实际控制人、5%以上股东签署《股份转让协议》暨控制权拟发生变更的提示 性公告显示，2025年5月30日晚间，菲林格尔实际控制人丁福如及其一致行动人新发展集团有限公司 （以下简称"新发展集团"）、广西巴马俪全饮料有限公司（以下简称"巴马俪全"）、上海多坤建筑工程 有限公司（以下简称"多坤建筑"）、ASIA PACIFIC GROUP INTERNATIONA LLIMITED（以下简称"亚 太集团"）与安吉以清科技合伙企业（有限合 ...